Skip to main content
. 2012 Sep;167(2):238–255. doi: 10.1111/j.1476-5381.2012.02008.x

Table 4.

Characterization of P2X receptors [Modified and updated from Burnstock (2003), with permission]

Receptor Main distribution Agonists Antagonists
P2X1 Smooth muscle, platelets, cerebellum, dorsal horn spinal neurones L-βγ-meATP ≥α,β-meATP = ATP = 2-MeSATP TNP-ATP, IP5I, NF023, NF449
PAPET-ATP (rapid desensitization) RO1, RO 0437626, NF279, MRS2159
P2X2 Smooth muscle, CNS, retina, chromaffin cells, autonomic and sensory ganglia ATP ≥ ATPγS ≥ 2-MeSATP >> α,β-meATP, β,γ-CF2ATP (pH + zinc sensitive) Suramin, RB2, NF770, isoPPADS, PSB-1011, NF778, aminoglycoside
P2X3 Sensory neurones, NTS, some sympathetic neurones 2-MeSATP ≥ ATP ≥α,β-meATP = Ap4A, PAPET-ATP (rapid desensitization) TNP-ATP, isoPPADS
A317491, NF110, RO4, RN-1838, spinorphin, AF353
P2X4 CNS, testis, colon ATP > α,β-meATP, CTP TNP-ATP and BBG (weak), BBG, Paroxetine, 5-BDBD, CORM 2, phenolphthalein
Ivermectin (potentiates)
P2X5 Proliferating cells in skin, gut, bladder, thymus, spinal cord ATPγS Suramin, PPADS, BBG
Ap4A
GTP
P2X6 CNS, motor neurones in spinal cord Does not function as homomultimer
P2X7 Apoptotic cells in immune cells, pancreas, skin, etc. BzATP > ATP ≥ 2-MeSATP > α,β-meATP KN62, KN04, MRS2427, BBG, o-ATP, Decavanadate, A-804598, RN-6189, AZD-9056, AZ10606120, A740003, A-438079, GSK-1370319

5-BDBD, 5-(3-bromophenyl)-1,3-dihydro-2H-benzofuro[3,2-e]-1,4-diazepine-2-one; BBG, brilliant blue G; NTS, nucleus tractus solitarii; PPADS, pyridoxalphosphate-6-azophenyl-2′,5′-disulfonic acid; TNP-ATP, 2′(3′)-O-(2,4,6-trinitrophenyl) ATP.